iwAL 2018 | Target antigens for T-cell engager therapies in ALL and AML

Marion Subklewe

T-cell engaging antibodies are more straightforward to deisgn and use in acute lymphoblastic leukemia (ALL) compared with acute myeloid leukemia (AML), and have thus had more success. Here, Marion Subklewe, MD, of LMU-University Hospital Munich, Munich, Germany, explains the reasons for this difference and how we can improve response rates to this type of therapy in AML. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.

Share this video